Feasibility and Safety of Remote Robotic Bronchoscopy System in Diagnosis of Peripheral Pu
Robotic bronchoscopy represents the latest localization technology for peripheral pulmonary nodules, enabling precise and stable manipulation, thereby enhancing the diagnostic yield of peripheral lung pathologies. Its safety and feasibility have been internationally validated, with indications that it can significantly
| Condition(s) | Pulmonary Nodule |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Robotic bronchoscopy represents the latest localization technology for peripheral pulmonary nodules, enabling precise and stable manipulation, thereby enhancing the diagnostic yield of peripheral lung pathologies. Its safety and feasibility have been internationally validated, with indications that it can significantly improve the overall diagnostic rate of biopsies for peripheral lung lesions. Nonetheless, the disparity in interventional auxiliary equipment and the level of technical operation is the primary cause for the significant variation in diagnostic rates of peripheral lung lesions across different regions, particularly in remote or underdeveloped areas. The advancement of 5G network technology has propelled the development of telemedicine, enabling remote diagnostics, surgeries, |
| Who can participate | Inclusion Criteria: Patients are eligible for inclusion if they meet all of the following criteria: Age ≥18 years and ≤75 years, with no gender restrictions; Presence of a peripheral lung lesion on chest CT \[Peripheral lung is defined as a nodule located in the fourth-order or higher airway (with the carina defined as order 0, the left and right main bronchi defined as order 1, lobar bronchi as order 2, segmental bronchi as order 3, and subsegmental bronchi as order 4)\] in patients who require biopsy \[2. The population requiring biopsy refers to individuals identified with an occupational lung lesion/nodule (including solid nodules, part-solid nodules, and ground-glass nodules) during clinical trial screening or with risk factors, and who, after comprehensive assessment by a clinician o |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Lead sponsor | Guangzhou Medical University |
| Locations | Guangzhou, Guangdong, China |
| Start date | 2024-09-15 |
| NCT ID | NCT06613412 |
| Official listing | https://clinicaltrials.gov/study/NCT06613412 |